Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
OT-551 in bilateral geographic atrophy
NCT00306488Phase 2Completed
- Sponsor
- National Institutes of Health
- Start
- Mar 2006
- Primary completion
- Mar 2010
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of OT-551 in geographic atrophy (GA) and age-related macular degeneration (AMD) (2 arms), sponsored by National Institutes of Health. Primary endpoint: Best-corrected Visual Acuity at 2 years. Started Mar 2006; status: completed.
02
Drugs
OT-551
03
Conditions
geographic atrophy (GA)age-related macular degeneration (AMD)
Beyond the preview
Go deeper on NCT00306488.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00306488.